Abstract
he high cost of treatment and large variation in the quality of patient care are major concerns in the treatment of type 2 diabetes mellitus. Increasing the degree of patient involvement in decisions related to treatment of their condition has been advocated in current T2DM guidelines and has been shown to improve the overall quality of care. This article presents preliminary results from the multicenter, cluster-randomized Diabetes Medication Choice Cards Trial in Greece [NCT01861756; EASD 2014 (poster 1077)] evaluating use of the Diabetes Medication Choice Decision Aids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
